Please use this identifier to cite or link to this item:
Title: Amitriptyline revisited : pharmacogenetic implications in antidepressant treatment
Authors: Mifsud Buhagiar, Luana
Grech, Anton
Serracino-Inglott, Anthony
LaFerla, Godfrey
Keywords: Pharmacogenetics
Depression, Mental -- Treatment -- Malta
Amitriptyline -- Therapeutic use -- Malta
Amitriptyline -- Research -- Malta
Cytochrome P-450 CYP2D6
Cytochrome P-450 CYP2C19
Issue Date: 2017-09
Publisher: University of Malta. Department of Pharmacy
Citation: Mifsud Buhagiar, L., Grech, A., Serracino Inglott, A., & LaFerla, G. (2017, September). Amitriptyline revisited: pharmacogenetic implications in antidepressant treatment. Poster session presented at the 77th FIP Annual Conference, Seoul, Republic of Korea.
Abstract: A poster presentation regarding amitriptyline and the pharmacogenetic implications in antidepressant treatment. Introduction: An interesting lead of pharmacogenomics is whether drug potential could be maximized through reattribution of medical purpose for drugs in which the balance between efficacy and toxicity has been difficult to strike in the general population. Tricyclic antidepressants (TCAs) are often overlooked in psychiatry on claims of poor tolerability, although cheaper with a potential efficacy advantage. Most data available on TCAs derives from an era when genotyping studies were not available. Aims: To assess whether genotyping is apt to translate biomarkers into individualised treatment with amitriptyline and whether harmonized labelling that allows interpretation of pharmacogenetic data can support in exploiting the benefit of a relatively inexpensive antidepressant.
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Amitriptyline_revisited_pharmacogenetic_implications_in_antidepressant_treatment_2017.pdf630.12 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.